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ABSTRACT
Introduction Diabetic retinopathy (DR) is a preventable 
cause of vision loss and blindness worldwide. We aim at 
analyzing the impact of a population- based screening 
program of DR using retinal photography with remote 
reading in terms of population coverage, diagnosis of 
asymptomatic DR and impact on visual disability, in the 
region of Andalusia, Spain, in the period 2005–2019.
Research design and methods Descriptive study. 
Sociodemographic and clinical features included in 
the Andalusian program for early detection of diabetic 
retinopathy (APDR) were analyzed. Population coverage, 
annual incidence of DR, and DR severity gradation were 
analyzed. Estimated data on prevalence and incidence of 
legal blindness due to DR were included.
Results 407 762 patients with at least one successful DR 
examination during the study period were included. Most 
of the performed retinographies (784 584, 84.3%) were 
‘non- pathological.’ Asymptomatic DR was detected in 52 
748 (5.9%) retinographies, most of them (94.2%) being 
classified as ‘mild to moderate non- proliferative DR.’ DR 
was detected in 44 815 patients, while sight- threatening 
DR (STDR) in 6256 patients; cumulative incidence of DR 
was 11.0% and STDR was 1.5%, as DR and STDR was 
detected in 44 815 and 6256 patients, respectively. Annual 
incidence risk per patient recruitment year progressively 
decreased from 22.0% by January 2005 to 3.2% by June 
2019.
Conclusions Implementation of a long- term population- 
based screening program for early detection of DR is 
technically feasible and clinically viable. Thus, after 15 
years of existence, the program has enabled the screening 
of the vast majority of the target population allowing the 
optimization of healthcare resources and the identification 
of asymptomatic DR.
INTRODUCTION
The region of Andalusia, which covers an area 
of 87 597 km2 in the south of Spain, has a popu-
lation of 8.4 million (18% of the country’s popu-
lation). The prevalence of diabetes is higher 
(15.3%) than in the rest of Spain (12.5%), in 
close relation to lifestyle and socioeconomic 
factors.1 Thus, Andalusia, as well as the rest of 
Europe, faces a rapid increase in their popula-
tion with chronic conditions (specifically with 
diabetes), which puts a high pressure on their 
public health systems.
The Andalusian Public Health System 
(APHS) is responsible for the provision of 
universal healthcare in the region and it 
comprises a wide network, with two levels of 
Significance of this study
What is already known about this subject?
 ► Diabetic retinopathy (DR) is the most frequent cause 
of new cases of blindness among adults aged 20–74 
years in developed countries. There is strong sup-
port for screening to detect DR, as severe forms are 
asymptomatic and an effective therapy to prevent 
blindness is available.
What are the new findings?
 ► In a public health system covering a large area of 
Southern Spain, a population- based screening pro-
gram using retinal photography with remote reading 
by experts is technically feasible and clinically viable.
 ► As a population- based screening program develops, 
annual incidence risk of DR significantly declines.
 ► After 15- year follow- up, a robust contribution of a 
population- based screening program in retinopathy- 
related health outcomes is shown.
How might these results change the focus of 
research or clinical practice?
 ► The higher incidence rates of asymptomatic DR that 
are found at the beginning of a population- based 
screening program within the context of a public 
healthcare system, should be considered in order to 
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care (1500 primary healthcare and 49 hospitals) based 
on accessible, high- quality, patient- centered care, in a 
system with universal coverage and funded by taxes.
Within the Andalusian health policy competences, the 
‘Comprehensive Healthcare Plan for Diabetes’ (CHPD), 
was developed in 2003 to improve the care provided and 
to reduce the incidence and impact in the region.2 It was 
focused on preventive activities and promoted changes 
for a healthy lifestyle, organization of healthcare delivery, 
training of professionals and research. Since then, the 
CHPD has been updated twice.3 4
Diabetic retinopathy (DR) is the most frequent micro-
vascular complication in people with diabetes, and its prev-
alence increases with the duration of the disease (overall 
rate, ≤30%), with a high risk of severe visual impairment 
(10% of patients).5 Thus, 20 years after diagnosis, most 
patients will have some degree of DR. Diabetes affected an 
estimated 422 million adults worldwide, with the number 
expected to rise to 642 million by 2040. Thus, the number 
of people with DR is expected to be increased.5–9
DR meets all required criteria to implement a system-
atic screening,10 so early detection and treatment has been 
claimed as the best strategy for preventing (or delaying) 
loss of vision.5 7 However, although detailed examina-
tion of the retina by an ophthalmologist is required for 
an accurate DR diagnosis, this highly resource and time- 
consuming process hinders the long- term sustainability of 
systematic screening programs. To overcome this problem, 
digital retinography was introduced as a first sorting- level 
in DR screening programs, achieving high levels of sensi-
tivity, specificity and a positive benefit- cost ratio.5 8 11 Unfor-
tunately, there are only few examples of population- based 
early detection screening programs with data assessment 
coming from long- term follow- up.6 9 12–19
Based on all these evidences and recommendations, 
a program for early detection of DR was incorporated 
in 2005 into the APHS and within the framework of the 
CHPD. This paper shows how the Andalusian program for 
early detection of diabetic retinopathy (APDR) was imple-
mented and its long- term impact between 2005 and 2019. 
Thus, the aims of this study, based on a long- term follow- up 
data of the Andalusian population diagnosed with diabetes, 
were:
i. to show how the population- based screening pro-
gram was deployed,
ii. to study the incidence of DR diagnosed within the 
framework of the screening program,
iii. to describe how incidence has changed over time,
iv. to show the potential of a population- based screening 
program to lower the burden of visual impairment of 
the Andalusian population diagnosed with diabetes.
RESEARCH DESIGN AND METHODS
Program description
The APDR targets the entire Andalusian population 
diagnosed with diabetes susceptible to being screened 
for DR according to clinical practice guidelines and 
without a previously known DR.4–6 20 There were no 
additional restrictions on participants’ demographics or 
characteristics.
The screening program is based on two stages: in the 
first one, digital retinographies are performed to the 
target population while, in the second one, retinogra-
phies that show positive or inconclusive results are trans-
ferred through a telematics platform to ophthalmology 
services for reassessment and patient referral to the 
ophthalmologist when necessary.
Patients eligible for screening were identified following 
the diabetes definition and the screening criteria estab-
lished by the American Diabetes Association.20 All target 
population is invited for periodic screening.
To assess the APDR feasibility, mainly in terms of 
healthcare professionals training, devices provision and 
outcomes assessment, a pilot project was launched in 
2004; it included 360 patients with diabetes, 11 primary 
care centers, and 6 hospitals centers. After a successful 
assessment, the program was extended progressively 
throughout the region.
Currently, the APDR works as follows:
 ► Patients with diabetes are invited to undergo retinal 
screening according to national clinical practice 
guidelines.21
 ► In primary care centers and endocrinology services 
in hospitals, trained nurses perform retinography, 
and the results are stored in the patient’s electronic 
health record within the corporate system (Diraya).
 ► DR screening is performed by assessment of the 
first retinography by a trained family physician in a 
primary care center for type 2 diabetes or an endo-
crinologist in a hospital, usually for type 1 diabetes.
 ► Patients for whom the results are negative are sched-
uled for the next examination cycle according to 
national clinical practice guidelines.21
 ► Retinographies that show positive or inconclu-
sive results are reviewed by an ophthalmologist for 
reassessment.
 ► Patients with DR (or any other pathological finding) 
are referred to an ophthalmology services through 
the digital platform for examination, confirmation of 
diagnosis, follow- up, and treatment if necessary.
The screening procedure is carried out by using digital 
retinographs after pupils are dilated with 1% tropicamide 
drops (unless contraindication). Three photographs of 
each fundus are taken, centered on the macula, nasal, 
and upper temporal fields, respectively.7 22 Each retinog-
raphy is transferred and stored in a central served once 
performed, so healthcare professionals in charge of 
retinographies grading can access for screening.
Quality control
Blind and randomized samples of retinographies classi-
fied as ‘normal’ were periodically assessed by ophthalmol-
ogists specialized in DR as internal auditors. This quality 
control procedure aims of detecting false negatives and, 
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Technological resources
Technological resources have increased progressively 
and distributed through the whole region, since the 
beginning of the program. Thus, 203 retinographers 
(including 44 mobile retinography units for covering 
certain rural areas) are available nowadays.
Data sources
Data on patient population (age, sex, years from diag-
nosis, type of diabetes, treatment, screening date, and 
screening result) were obtained from the APDR registry. 
These data were complemented with those included in 
the Health Population Data Base (HPDB) of Andalusia 
(which includes personal and health- related data). For 
each patient, data from APDR and HPDB are linked 
thanks to the existence of a unique citizen/patient iden-
tifier system within the APHS, that ensures that everyone 
is correctly identified, treated, and followed up within 
the system.
Data on Andalusian population were obtained from 
the Spanish National Statistics Institute (INE) website.23
Neither Andalusia nor Spain has implemented corpo-
rate registries of disability or legal blindness due to 
DR. However, the vast majority of Spanish blind people 
or suffering serious visual impairment are members of 
the Organización Nacional de Ciegos Españoles (the 
Spanish National Association for the Blind, ONCE) 
since they have access to benefits and specialized social 
services.24 To be a member, at least one of the following 
visual requirements must be met: (i) visual acuity ≤0.1 
(obtained with the best possible optical correction) and 
(ii) Visual field reduced to 10 degrees (or less).25 Thus, 
ONCE provided the number of its Andalusian members, 
as well as those members (new and total) diagnosed with 
diabetes and DR in the region per year.
Study population
The study includes all patients with diabetes registered 
in the APDR from January 2005 to June 2019. This group 
of patients constitutes a dynamic cohort, where individ-
uals can enter (due to diabetes diagnosis) or leave the 
cohort (eg, when DR is confirmed, abandonment of the 
program or death of patient). These data come from of 
a continuous- time process of observations at screening 
visits. Only data coming from people without DR that had 
at least one successful DR examination were included.
Given the aim of the program and an overall preva-
lence of DR ≤30%, the target population was estimated 
in the 70% of the entire diabetic population registered in 
electronic corporate database. Main characteristics of the 
studied population are shown in table 1.
Data analysis
Retinographies with DR signs were graded according to 
the International Clinical Diabetic Retinopathy Severity 
Scale.26 DR was graded in no DR, mild, moderate, or 
severe non- proliferative DR, and proliferative DR. When 
severity differences were found in each patient eye, the 
most severe one was selected.
The finding of any DR grade was considered as posi-
tive screening result. Any DR grade equal to or greater 
than severe non- proliferative DR was classified as sight- 
threatening diabetic retinopathy (STDR).
Descriptive statistic was used to depict main character-
istic of the cohort. Mean value, SD, and CI were used as 
descriptors.
Incidence was calculated as cumulative incidence by 
dividing the number of new DR cases by the respective 
number of people at risk (patients included without a 
previously known DR). Therefore, these assessments 
were performed to the cohort as a whole and per cohort 
subgroups and per year of patient recruitment within the 
program. In addition, 95% CIs for cumulative incidence 
rates were also calculated.
All statistical analyses were carried out using the 
RStudio software V.1.2.1335 (RStudio, Boston, USA).
RESULTS
Program coverage
There were 429 791 patients included within the APDR 
with, at least, one performed test, of which, 16 531 
Table 1 Sociodemographic and clinical characteristics of 
included population
Mean SD
Age (years) 62.8 12.8
Years from diagnosis 6.4 6.9
Gender n %
  Male 222 574 54.6%
  Female 185 188 45.4%
Age (years)   
  <35 9950 2.4%
  35–64 202 032 49.6%
  >65 195 780 48.0%
Diabetes type   
  Type 1 diabetes 18 250 4.5%
  Type 2 diabetes 386 895 94.9%
  Others 2617 0.6%
Years from diagnosis   
  <5 205 577 50.4%
  5–9 101 537 24.9%
  10–19 78 934 19.4%
  ≥20 21 714 5.3%
Drug treatment   
  Insulin (only) 26 108 6.4%
  Non- insulin treatments 231 674 56.8%
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patients without results fully assessed and 413 260 with 
results: from them, 5498 patients had a previously known 
and treated DR, and 407 762 people without previously 
known DR between January 2005 and June 2019. This 
means a total follow- up of 1 182 211 persons- year and an 
average of 2.9 years per screening cycle. Main sociodemo-
graphic and clinical characteristics of the studied popu-
lation at the entrance of the APDR are shown in table 1.
The estimated program coverage shows a practically 
linear growth since the beginning of the program. 
Assuming that target population would be 70% of Anda-
lusian diabetic population, in 2011, nearly half of the 
target population of the program (48.9%) was reached. 
After 3 years, it quickly rose until reaching around 75% 
and, by the end of 2018, almost 90% of the target popula-
tion was reached (online supplementary figure S1).
Main program results
Within the study period, 888 318 retinographies were 
performed, so 2.22±1.47 (mean±SD) retinographies per 
patient were performed. 84.3% retinographies (784 584) 
were classified as ‘non- pathological’, 52 315 (5.9%) were 
not evaluable, and 28 913 (3.3%) showed other findings. 
Asymptomatic DR (any DR grade) was detected in 52 748 
(5.9%) retinographies, the majority of them (94.2%) 
being classified as ‘mild to moderate non- proliferative 
DR.’
To date, none of the quality control samples have been 
classified as false negative that requires immediate/
urgent treatment were found.
Diabetic retinopathy incidence
DR was detected in 44 815 patients, while STDR in 6256 
patients, so cumulative incidence of DR and STDR was 
11.0% (95% CI 10.8 to 11.1) and 1.5% (95% CI 1.5 to 
1.6), respectively.
DR incidence was slightly higher in men and at 
younger ages. Moreover, it prevailed in patients with type 
1 diabetes. However, it seems that the most important 
factor is the time from diabetes diagnosis. Thus, DR 
incidence is four times higher in patients with a known 
diabetes progression exceed 20 years than in those with 
less than 5 years of evolution (table 2).
Regardless of the date of inclusion, most DR cases 
(92%) were detected in the first three examination cycles 
and, more specifically, 64% of total cases were detected in 
the first one. Regarding the sequence of retinographies 
performed in each patient, DR and STDR incidence in 
the first screening cycle was, at least, twice that in the 
second one and decreased progressively in subsequent 
cycles (online supplementary figure S2).
Table 2 Diabetic retinopathy incidence rates per sociodemographic and clinical characteristics
DR STDR
Incidence 95% CI Incidence 95% CI
Gender
  Male 11.39 11.26 to 11.52 1.60 1.55 to 1.65
  Female 10.51 10.37 to 10.65 1.45 1.40 to 1.51
Age (years)         
  <35 12.87 12.22 to 13.55 1.60 1.36 to 1.86
  35–64 11.57 11.43 to 11.71 1.77 1.71 to 1.82
  >65 10.30 10.16 to 10.43 1.29 1.24 to 1.34
Diabetes type         
  Type 1 diabetes 15.04 14.52 to 15.56 2.12 1.91 to 2.33
  Type 2 diabetes 10.82 10.73 to 10.92 1.51 1.47 to 1.55
Years from diagnosis         
  <5 6.47 6.36 to 6.58 0.82 0.78 to 0.86
  5–9 12.14 11.94 to 12.34 1.60 1.52 to 1.68
  10–19 16.94 16.68 to 17.21 2.48 2.38 to 2.60
  ≥20 26.79 26.20 to 27.39 4.50 4.23 to 4.78
Drug treatment of diabetes         
  No treatment 9.49 9.32 to 9.67 1.22 1.15 to 1.28
  Insulin (only) 23.84 23.33 to 24.36 3.85 3.62 to 4.09
  Non- insulin treatments 8.14 8.03 to 8.25 1.06 1.02 to 1.10
  Combination of treatments 23.68 23.26 to 24.11 3.73 3.55 to 3.93
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Annual incidence risk per APDR recruitment year also 
progressively decreased from 22.0% by December 2005 
to 3.2% by June 2019 (figure 1A). Slight differences were 
also found in annual incidence risk of DR by gender, 
age, type of diabetes and per years from diagnosis 
(figure 1B–E).
Diabetic retinopathy-related legal blindness
The percentage of new annual ONCE registrations in 
Andalusia due to DR decreased regarding new annual 
registrations, from 12.8% in 2004 to 6.1% in 2018. In the 
same way, the incidence and prevalence of DR among 
ONCE members per 1000 people with diabetes fell 
dramatically over the last decade from 20.1 to 4.6 and 
from 2.5 to 1.5, respectively (figure 2).
CONCLUSION
Our work provides the main population- based screening 
program of Spain in terms of people with diabetes covered 
(407 762 people with at least one successful DR exam-
ination), and the second one in the world, as far as we 
know, just after NHS Diabetic Eye Screening Program in 
England.13 Despite being a regional screening program, 
the number of people covered and screened in this study is 
far ahead of those shown in other publications that tackle 
country and regional screening programs.6 12 14 16–18 27 28
Identification of new cases of DR was concentrated 
just following the launch of the APDR and in the first 
screening cycles of each patient; a dramatic lower 
annual incidence risk of DR was detected at the end of 
follow- up. This striking pattern could be due to different 
reasons. First, the main justification for implementing a 
population- based DR screening program in our region 
was the evidence of low adherence to periodic retinop-
athy screening related to insufficient access to ophthal-
mology services.2 Thus, implementation of a new DR 
screening program would make a relevant initial pool of 
undiagnosed DR emerge. As extension of the program 
was progressive, this downward trend was maintained 
along the analyzed period. Second, when years from diag-
nosis were analyzed, earlier recruitment was progressively 
achieved and accordingly, less risk of developing DR. 
Thus, the average elapsed time from diabetes diagnosis 
to inclusion in APDR was 3 years lower among patients 
included at the end of the analyzed period in compar-
ison with the ones included at the launch of the program. 
Finally, better access to medical care and improved 
educational, pharmacological, and technological 
resources for diabetic population could also contribute 
Figure 1 Annual incidence risk of DR and STDR per patient recruitment year in the APDR. Results are expressed as % of total 
number of patients with diabetes enrolled within APDR. Vertical bars represent the 95% CI. APDR, Andalusian Program for 
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to decreased rates of DR in last years. In any case, the 
higher incidence rates that are found at the beginning of 
this kind of programs should always be considered when 
a population- based screening program is implemented 
within the context of a public healthcare system, in order 
to plan human and technological resources and warrant 
ophthalmological assistance.
After 15 years of data collection in Andalusia, main 
variables associated with the DR incidence were years 
from diagnosis of diabetes and patient age. This result 
is consistent with other publications.14 15 17 29 Most RD 
cases (95% of screened population) were identified in 
people with type 2 diabetes, although the probability of 
RD among type 1 diabetes population is higher than in 
type 2 diabetes.
DR screening programs worldwide have varied in 
terms of sample size, demographic of patients, inclu-
sion criteria, follow- up period, type of diabetes and even 
grading protocols employed, limiting the comparison of 
results in terms of DR detection.9 17 Among the European 
studies, the main one (in terms of people screened) was 
carried out by Scanlon. He assessed the results of the 
English NHS Diabetic Eye Screening Program for DR; in 
2015–2016, this program reached a coverage of 82.8%, 
when 2.14 million people were screened, and a rate of 
retinopathy was 2807 per 100 000 screened patients was 
found.13 In Italy, a decade of telemedicine program for 
screening DR in a large metropolitan area of North East 
of Italy (where 9347 patients with type 1 diabetes and 
type 2 diabetes were followed from 2005 to 2015) was 
assessed by Vujosevic et al. In this study, the overall inci-
dence of STDR was 3.1% during the 10- year follow- up.14 
In Portugal, within the context of the 5- year retrospective 
analysis of the RETINODIAB study (55 496 patients with 
type 2 diabetes were studied between 2009 and 2014), 
showed a cumulative incidence of 16.3%; on the other 
hand, in a study carried out by Ribeiro et al in the Central 
Region of Portugal following 45 148 patients with type 1 
diabetes and type 2 diabetes from 2011 to 2014, higher 
rates of DR (25.0%) were found.6 17 These cumulative 
incidence differences might be mainly due to dispari-
ties in the inclusion criteria in each screening programs. 
Thus, in the work of Ribeiro et al only treatment for 
‘STDR’ was considered exclusion criteria, so other cases 
of DR would be included.
In Spain, most studies report data from a very limited 
area and sample size.16 29 30 The cumulative incidence 
of DR found in the MADIABETES Study (a prospective 
cohort study where 3443 outpatients with type 2 diabetes, 
followed up from 2008 to 2011) was 8.1%.29 On the 
other hand, the study published by Romero- Aroca et al 
in 2016 (a prospective population- based study carried 
Figure 2 New and accumulated ONCE affiliations cases due to DR in Andalusia (2004–2019). Frequency is calculated 
according to Andalusian population (general) and to Andalusian diabetic population (Diabetes), respectively. DR, diabetic 
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out in the north- east of Spain, where 15 396 patients with 
diabetes, were screened between 2007 and 2014) found 
a yearly mean incidence value of 8.4% (increasing from 
8.1% in 2007 to 8.9% in 2014).15 They also observed 
that, although incidence remained stable between 2007 
and 2011 (8.1%), it rose to 8.8% in 2012, and remained 
after that more or less stable (8.9% in 2013 and 8.9% in 
2014).15 These differences might be due to the methods 
used to detect DR and data analysis and to the regional 
inequalities in the prevalence of visual impairment 
and blindness (correlated with concomitant diseases, 
regional level of economic development, rural environ-
ment, ultraviolet light exposure, or gender inequalities, 
among others).15 16 29 30
As well as most screening programs, APDR is not 
designed to assess neither DR severity nor its progres-
sion. Nevertheless, in line with other publications, a first 
approximation of data comparison can be performed. 
Thus, most of the performed retinographies (84.3%) 
were classified as ‘non- pathological’, reducing the work-
load of the ophthalmology services. Asymptomatic DR was 
only detected in 5.9% of retinographies, 94.2% of them 
being classified as ‘mild to moderate non- proliferative 
DR.’ On the other hand, one in seven patients with DR 
detected (14%) has STDR. These patients are susceptible 
to immediate treatment, and their referral to ophthal-
mology services should be prioritized. This issue needs to 
be considered in the design phase of a population- based 
screening program to ensure the availability of resources.
In comparison with other studies assessing DR severity 
within screening DR programs at European level, in 
the study carried out by Vujosevic in Italy, most patients 
(86.3%) showed ‘mild’ or ‘moderate’ DR.14 In Portugal, 
in the RETINODIAB study, only 71.5% of the results 
were non- pathological, in contrast with the 83.7% 
obtained in the study performed by Dutra Medeiros et 
al.6 17 The MADIABETES study showed that 49.5% of 
cases were classified as ‘non- proliferative DR’ and 35.1% 
as ‘proliferative DR’; of those cases classified as ‘non- 
proliferative DR’, 88.5% were classified as ‘mild’ and 
11.5% as ‘moderate’ or ‘severe.’29 In the study published 
by Romero- Aroca, although most cases were classified 
as ‘mild’ or ‘moderate’ DR, a progressive increase of 
most severe cases (‘severe’ and ‘proliferative’ DR) from 
2010 to 2014 was observed.15 These slight discrepancies 
might also be due to the aforementioned differences in 
methods used, as well as the intra/interterritorial differ-
ences in the disease pattern.
On the other hand, a positive tendency on ONCE data 
were also observed. Thus, the reduction on the incidence 
and prevalence of DR per 1000 ONCE’s members with 
diabetes fell 15.5 and 1 points, respectively, so it can be 
inferred that the implementation of the APDR has shown 
clinical effectiveness due to its real impact on the compli-
cations in people with diabetes.
The quality and performance of the program has been 
recognized as good practice by two independent organ-
isms, the Spanish Ministry of Health and the WHO.31–33 
These recognitions mean that the APDR fulfills all 
requirements for and is ready to provide the needed 
information to any healthcare systems that would be 
interested to implement it. Moreover, new technologies 
could improve our DR screening strategy and their cost- 
effectiveness. In addition, emerging evidence suggests 
that retinal imaging could add the role of DR to other 
diseases beyond the prevention of sight- threatening 
disease.34
The strengths of our study include the progressive 
program implementation after an initial feasibility assess-
ment based on a pilot project. Furthermore, the large 
sample size is one of the main strengths of this study. More-
over, it is the main national population- based screening 
program in terms of population coverage and the second 
one worldwide. Therefore, the analyzed sample would 
be representative of the Andalusian diabetic population. 
Outcome assessment is based on long- term monitoring, 
where disease criteria have not been altered.
Conversely, only DR incidence estimations can be calcu-
lated, as our results come from clinical practice obser-
vation and could lack the robustness of epidemiological 
studies. As there is a lack of an official database of visual 
disability due to DR, the real impact of the APDR on prev-
alence and incidence of visual impairment in diabetic 
Andalusian population cannot be accurately calculated.
The results of the APDR demonstrate the success of 
the implementation of a long- term population- base 
screening program for DR, since the program coverage 
rose rapidly while incidence of asymptomatic DR progres-
sively decreased. After 15 years of activity, the APDR 
has enabled the screening of the vast majority of target 
population, the rapid identification of asymptomatic 
DR cases in Andalusia, and the optimization of health-
care resources of the Andalusian Public Healthcare 
System. These results reinforce the need and feasibility 
of programs focused on early detection of DR in public 
health systems.
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